Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7757)
All Articles published online
|
Publishing Process of This Article
|
Mar 14, 2018 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sun L, Li PB, Yao YF, Xiu AY, Peng Z, Bai YH, Gao YJ. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2018; 24(10): 1120-1133 [PMID: 29563756 DOI: 10.3748/wjg.v24.i10.1120] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i10/1120.htm |
| Number | Citing Articles |
| 1 |
Jordan C. LeSarge, Pierre Thibeault, Lihai Yu, Marina D. Childs, Victor M. Mirka, Qi Qi, Matthew S. Fox, Michael S. Kovacs, Rithwik Ramachandran, Leonard G. Luyt. Protease-activated receptor 2 (PAR2)-targeting peptide derivatives for positron emission tomography (PET) imaging. European Journal of Medicinal Chemistry 2023; 246: 114989 doi: 10.1016/j.ejmech.2022.114989
|
| 2 |
Kiman Kim, Jinyong Lee, Sungho Ghil. The regulators of G protein signaling RGS16 and RGS18 inhibit protease‐activated receptor 2/Gi/o signaling through distinct interactions with Gα in live cells. FEBS Letters 2018; 592(18): 3126 doi: 10.1002/1873-3468.13220
|
| 3 |
Kenjiro Kaji, Noriyuki Kaji, Masatoshi Hori, Kosei Sakai, Tomohiro Yonezawa, Shingo Maeda. Protease-Activated Receptor-2 Is Associated With Adverse Outcomes in Canine Mammary Carcinoma. Veterinary Pathology 2021; 58(1): 53 doi: 10.1177/0300985820963087
|
| 4 |
Moeno Kume, Ayesha Ahmad, Kathryn A. DeFea, Josef Vagner, Gregory Dussor, Scott Boitano, Theodore J. Price. Protease-Activated Receptor 2 (PAR2) Expressed in Sensory Neurons Contributes to Signs of Pain and Neuropathy in Paclitaxel Treated Mice. The Journal of Pain 2023; 24(11): 1980 doi: 10.1016/j.jpain.2023.06.006
|
| 5 |
Yuhong Jiang, Xin Zhuo, Xiujuan Fu, Yue Wu, Canquan Mao. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.625289
|
| 6 |
Hendrik Ungefroren, Frank Gieseler, Roland Kaufmann, Utz Settmacher, Hendrik Lehnert, Bernhard H. Rauch. Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer. International Journal of Molecular Sciences 2018; 19(6): 1568 doi: 10.3390/ijms19061568
|
| 7 |
Y. Bareche, D. Kelly, F. Abbas-Aghababazadeh, M. Nakano, P.N. Esfahani, D. Tkachuk, H. Mohammad, R. Samstein, C.-H. Lee, L.G.T. Morris, P.L. Bedard, B. Haibe-Kains, J. Stagg. Leveraging big data of immune checkpoint blockade response identifies novel potential targets. Annals of Oncology 2022; 33(12): 1304 doi: 10.1016/j.annonc.2022.08.084
|
| 8 |
Yuhong Jiang, Xin Zhuo, Yue Wu, Xiujuan Fu, Canquan Mao. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2022; 1869(1): 119144 doi: 10.1016/j.bbamcr.2021.119144
|
| 9 |
Kaushik Das, Subhojit Paul, Arpana Singh, Arnab Ghosh, Abhishek Roy, Shabbir Ahmed Ansari, Ramesh Prasad, Ashis Mukherjee, Prosenjit Sen. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition. Journal of Biological Chemistry 2019; 294(37): 13681 doi: 10.1074/jbc.RA119.008619
|
| 10 |
Nisha R. Pawar, Marguerite S. Buzza, Toni M. Antalis. Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2–Mediated Signaling: Co-Conspirators in Cancer Progression. Cancer Research 2019; 79(2): 301 doi: 10.1158/0008-5472.CAN-18-1745
|
| 11 |
Juncheng Guo, Min Guo, Jinfang Zheng. Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway. Cancer Management and Research 2021; : 773 doi: 10.2147/CMAR.S281969
|
| 12 |
Himani Shah, Timothy A. Hill, Junxian Lim, David P. Fairlie. Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells. Journal of Cell Communication and Signaling 2023; 17(4): 1293 doi: 10.1007/s12079-023-00791-6
|
| 13 |
Qiaoyan Si, Mingjian Bai, Xiaolong Wang, Tianyu Wang, Yan Qin. Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1420463
|
| 14 |
P SUHAJ, T OLEJAR, R MATEJ. PAR2: The Cornerstone of Pancreatic Diseases. Physiological Research 2022; : 583 doi: 10.33549/physiolres.934931
|
| 15 |
Yuhong Jiang, Junxian Lim, Kai‐Chen Wu, Weijun Xu, Jacky Y. Suen, David P. Fairlie. PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR. British Journal of Pharmacology 2021; 178(4): 913 doi: 10.1111/bph.15332
|